10-Q · May 15, 2026
Aspire Biopharma reported a substantial improvement in revenue and a notable decrease in net loss compared to the prior year, indicating an evolving operational trajectory. However, management highlighted ongoing…
Earnings analysis · 10-Q
ASBP earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q does not include current-quarter income statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so operating trends cannot be assessed from the filing. The principal negative…
Read full summary
The extracted 10-Q does not include current-quarter income statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so operating trends cannot be assessed from the filing. The principal negative signal is ineffective disclosure controls as of June 30, 2026, specifically including recapitalization accounting. Aspire raised $20,000,000 through issuance of 26,250 preferred shares during the six months ended June 30, 2026, while additional common-share issuances create meaningful dilution risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Raised $20 million in preferred financing
Aspire issued 26,250 shares of Series A Convertible Preferred Stock for gross proceeds of $20,000,000 during the six months ended June 30, 2026, providing additional financing.
-
No share repurchases
The filing reports no equity repurchases during either the three or six months ended June 30, 2026, preserving cash that otherwise could have been used for buybacks.
-
No insider trading-plan changes
The company disclosed that no directors or officers adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the three and six months ended June 30, 2026.
What to watch
-
Material weakness in disclosure controls
Management and the CEO and CFO concluded that disclosure controls and procedures were not effective as of June 30, 2026, including controls surrounding complex accounting areas such as the recapitalization.
-
Substantial equity dilution
The six-month financing and other transactions included 26,250 preferred shares, 26,333 common incentive shares, 21,525 common shares issued to lenders, and 207 true-up shares, creating dilution risk for existing holders.
-
No formal risk-factor update
The company states that there were no material changes to the risk factors in its December 31, 2025 Form 10-K. Accordingly, no new formal risk-factor changes were identified in this 10-Q.
Management's outlook
The 10-Q does not provide quantitative revenue or EPS guidance; outlook was not provided in the extracted filing.
Earlier filings 4
10-K · March 30, 2026
Aspire Biopharma reports positive early clinical and regulatory progress for its patent-pending sublingual delivery technology (completed a July 2025 bioavailability study with final report received September 5, 2025)…
10-Q · May 14, 2025
Aspire Biopharma reported no revenue and a net loss of $15,941,328 for the quarter ended March 31, 2025, driving diluted EPS of $(0.42) compared with a net loss of $230,970 (EPS $(0.01)) in the prior-year quarter. Cash…
10-K · March 11, 2024
PowerUp Acquisition Corp. is pursuing a merger with Visiox Pharmaceuticals, focusing on late-stage pharmaceutical opportunities due to favorable market conditions. The company has extended its business combination…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.